As the only country in the G8 without an orphan drugs act, the President of Médunik, a company focused on bringing orphan drugs into the country,…
In Conversation
An interesting perspective on the Canadian market, and its opportunities and challenges in drug registration on a regional level from the President of Triton Pharma, a…
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as…
The CEO of MaRS Innovation, a commercialization incubator created by 16 of Toronto's best research institutions and supported by the government, assesses Toronto's merits as an…
Minister Marceau addresses the changes in policy in Quebec relating to the pharmaceutical and life sciences sectors, and the incentives in place to make the state…
A perspective from Canada’s national health body on the future of medicine in the 21st century, from the shift to personalized medicine to streamlining regulatory and…
The President & CEO of Sanofi Canada talks candidly about the pros and cons of the current administrative setup of the Canadian healthcare sector; Concerto, an…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company's regulatory struggles, the utilization of Almirall’s global R&D infrastructure…
BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives…
World Courier's national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director…
